statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine Biosciences Launches INGREZZA SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

Neurocrine Biosciences Launches INGREZZA SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing Neurocrine Biosciences Launches INGREZZA...

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial...

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH Neurocrine Biosciences Announces U.S. FDA...

Neurocrine Biosciences Presented CAHtalyst Phase 3 Pediatric and Adult Studies, CAHtalog Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024

Neurocrine Biosciences Presented CAHtalyst Phase 3 Pediatric and Adult Studies, CAHtalog Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 Neurocrine Biosciences...

Neurocrine Biosciences Announces Publication of Primary CAHtalyst Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Neurocrine Biosciences Announces Publication of Primary CAHtalyst Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine Neurocrine...

Neurocrine Biosciences Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Neurocrine Biosciences Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine Neurocrine Biosciences...

Neurocrine Biosciences to Participate at Investor Conferences in June

Neurocrine Biosciences to Participate at Investor Conferences in June Neurocrine Biosciences to Participate at Investor Conferences in June PR Newswire SAN DIEGO, May 29, 2024 Jefferies Global...

Neurocrine Biosciences Announces CEO Succession Plan

Neurocrine Biosciences Announces CEO Succession Plan Neurocrine Biosciences Announces CEO Succession Plan PR Newswire SAN DIEGO, May 28, 2024 Board of Directors appoints Kyle Gano, Ph.D., Chief...

Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at...

Neurocrine Biosciences Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA (valbenazine) Capsules

Neurocrine Biosciences Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA...

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Volume	744,764.00
52-Wk High	$150.39
52-Wk Low	$99.98

NBIX Neurocrine Biosciences, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals